未见利妥昔单抗的长期潜在毒性。
No long-term toxicity potentially due to rituximab was observed.
结论使用利妥昔单抗治疗应严密监护，保证用药安全。
Conclusion the use of rituximab treatment should be closely monitored to ensure the safety of drug use.
结论：利妥昔单抗联合CHOP方案治疗DLBCL，疗效好，不良反应小。
Conclusion: Combination treatment of rituximab and CHOP is effective and of little side effect.
更多的利妥昔单抗组的患者在第一次注射后发生不良反应，大多数都是1或2级的。
More patients in the rituximab group than in the placebo group had adverse events, mostly grade 1 or grade 2, after the first infusion.
另外，相对于安慰机组，利妥昔单抗组的糖化血红蛋白和胰岛素必须量都明显较低。
The rituximab group also had significantly lower levels of glycated hemoglobin and required less insulin.
在向FDA申报批准的临床研究中，大部分病人都对苯达莫司汀和利妥昔单抗耐药。
In the study that led to the FDA approval, most patients were refectory to bendamustine and rituximab.
免疫抑制剂治疗，如利妥昔单抗，硫唑嘌呤和环磷酰胺，明显减少抗体水平和复发率。
Treatment with immunosuppressants such as rituximab, azathioprine and cyclophosphamide resulted in a marked reduction in antibody levels and relapse rates.
已报道有关利妥昔单抗的毒性表皮坏死，但毒性表皮坏死和苯达莫司汀的关系尚不确定。
Toxic epidermal necrolysis has been reported for rituximab, but the relationship of toxic epidermal necrolysis to bendamustine has not been determined.
此外，一项二期研究将利妥昔单抗和pembrolizumab联合来治疗复发的滤泡性淋巴瘤。
Additionally, a phase II study is looking at the combination of rituximab and pembrolizumab (Keytruda) for patients with relapsed follicular lymphoma (NCT02446457).
结论：利妥昔单抗联合CEOP方案治疗侵袭性B细胞淋巴瘤疗效高而不良反应轻，有望成为标准治疗。
Conclusions: the combination of MabThera and CEOP regimen had high efficacy with mild toxicity in the treatment of aggressive B-cell lymphoma, hopefully may become the standard treatment.
先前未经治疗、而对利妥昔单抗诱导缓解有效后接受延长治疗的患者中，8年有45%患者仍无事件发生。
Of previously untreated patients receiving prolonged treatment after responding to rituximab induction, at 8 years 45% were still without event.
目的探讨抗肿瘤靶向药物利妥昔单抗（美罗华）不良反应的特点及规律，为临床安全、合理用药提供参考。
Objective To investigate the adverse reactions of rituximab (Rituxan and MabThera) in retrospection to provide references for safe and rational drug use clinically.
我们的研究旨在评价利妥昔单抗加化疗一线治疗的滤泡性淋巴瘤患者使用利妥昔单抗维持治疗2年的疗效。
We assessed the potential benefit of 2 years of rituximab maintenance after first-line treatment in patients with follicular lymphoma receiving a rituximab plus chemotherapy regimen.
用利妥昔单抗治疗难治性ANCA相关性血管炎时，其缓解率可达80%到90%，可能比环磷酰胺疗法更安全。
Treatment with rituximab has led to remission rates of 80 to 90% among patients with refractory ANCA-associated vasculitis and may be safer than cyclophosphamide regimens.
目的观察利妥昔单抗联合CHOP方案(R - CHOP)治疗初治弥漫大B细胞型淋巴瘤的疗效以及毒副反应。
Objective to observe the effect and toxicity of rituximab and CHOP regimen (R-CHOP) in the treatment of initially diagnosed diffuse large B-cell lymphoma.
怀孕前应终止使用的药物包括甲氨蝶呤、来氟米特和一些生物制剂包括抗肿瘤坏死因子制剂、利妥昔单抗和阿巴西普。
Drugs recommended to be stopped before pregnancy include methotrexate and leflunomide, plus the biologics: anti-TNF agents, rituximab and abatacept.
阐释：滤泡性淋巴瘤患者在免疫化疗作为一线治疗后使用利妥昔单抗维持治疗2年，能显著改善无进展生存（PFS）。
INTERPRETATION: 2 years of rituximab maintenance therapy after immunochemotherapy as first-line treatment for follicular lymphoma significantly improves PFS.
背景：目前，弥漫大b细胞性淋巴瘤(DLBCL)的标准治疗方案为利妥昔单抗联合CHOP方案化疗(R - CHOP)。
PURPOSE: the current standard therapy for patients with diffuse large B-cell lymphoma (DLBCL) is rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).
在一个30例患者的小规模研究中，pidilizumab加利妥昔单抗在复发的滤泡性淋巴瘤中取得了66%的总有效率，其中大部分是完全缓解。
In a small 30-patient study, pidilizumabplus rituximab demonstrated an ORR of 66% in relapsed follicular lymphoma, which primarily consisted of complete responses.
2016年2月底，FDA批准了对接受过利妥昔单抗治疗的滤泡性淋巴瘤患者使用抗CD20单抗obinutuzumab和苯达莫司汀联合的方案。
In late February 2016, the FDA approved the anti-CD20 agent obinutuzumab(Gazyva) in combination with bendamustine for patients with follicular lymphoma following rituximab-based therapy.
2016年2月底，FDA批准了对接受过利妥昔单抗治疗的滤泡性淋巴瘤患者使用抗CD20单抗obinutuzumab和苯达莫司汀联合的方案。
In late February 2016, the FDA approved the anti-CD20 agent obinutuzumab(Gazyva) in combination with bendamustine for patients with follicular lymphoma following rituximab-based therapy.
应用推荐